



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 541 120 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:

26.05.1999 Bulletin 1999/21

(51) Int Cl.⁶: C07D 473/04, A61K 31/52

(21) Application number: 92119080.7

(22) Date of filing: 06.11.1992

(54) Xanthine derivatives for the treatment of dementia

Xanthinderivate zur Behandlung der Demenz

Dérivés de Xanthine pour le traitement de la démence

(84) Designated Contracting States:

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE

(30) Priority: 08.11.1991 JP 293269/91

(43) Date of publication of application:
12.05.1993 Bulletin 1993/19

(73) Proprietor: KYOWA HAKKO KOGYO CO., LTD.
Chiyoda-ku, Tokyo-to (JP)

(72) Inventors:

- Fumio, Suzuki
Mishima-shi, Shizuoka-ken (JP)
- Junichi, Shimada
Sunto-gun, Shizuoka-ken (JP)
- Hiromasa, Kato
Sunto-gun, Shizuoka-ken (JP)
- Akio, Ishii
Sunto-gun, Shizuoka-ken (JP)
- Shizuo, Shiozaki
Fuji-shi, Shizuoka-ken (JP)

(74) Representative: VOSSIUS & PARTNER

Postfach 86 07 67
81634 München (DE)

(56) References cited:

EP-A- 0 203 721	EP-A- 0 374 808
EP-A- 0 386 675	EP-A- 0 415 456
EP-A- 0 501 379	WO-A-92/00297
DE-B- 1 245 969	

- MOLECULAR PHARMACOLOGY vol. 33, no. 6, June 1988, BALTIMORE pages 585 - 591 AMRAT PATEL ET. AL.
- JOURNAL OF MEDICINAL CHEMISTRY vol. 31, no. 4, April 1988, WASHINGTON pages 745 - 751 JOEL LINDEN ET. AL.

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification


EP 0 541 120 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description


[0001] The present invention relates to xanthine derivatives having anti-dementia activity and being useful as an anti-dementia drug.

[0002] Xanthine derivatives have been hitherto known in the prior art. For example, USP 5068236 (Japanese Published Unexamined Patent Application No. 173888/92) discloses xanthine derivatives of the formula:




20 wherein R^A and R^B are lower alkyl; and R^C and R^D are substituted or unsubstituted alicyclic alkyl. The xanthine derivatives have exhibited diuretic activity, renal protecting activity and vasodilator activity.

[0003] EP 415456A (Japanese Published Unexamined Patent Application No. 173889/92) discloses xanthine derivatives of the formula:



35 wherein R^E and R^F is lower alkyl; and Q^A represents



or




55 (wherein --- is a single bond or double bond; YA is a single bond or alkylene; and n^a is 0 or 1).

[0004] Molecular Pharmacology, 33, 585 (1988) discloses a xanthine derivative of the formula:

5

10


15

20 which has adenosine A₁ antagonistic activity.[0005] Journal of Medicinal Chemistry, 31, 745 (1988) discloses a xanthine derivative of the formula:

25

30


35

40 which has adenosine A₁ antagonistic activity.[0006] European Journal of Medicinal Chemistry, 25, 653 (1990) discloses xanthine derivatives of the formula:

45

50


55



wherein Q^B is alkyl. The xanthine derivatives have bronchodilator activity.

[0007] CA 724173 discloses xanthine derivatives of the formula:

5




10

15 R^G and R^H are alkyl or aralkyl; and Q^C is cycloalkyl. The xanthine derivatives have diuretic activity.

[0008] Further, WO 86/01724 discloses an insecticide containing xanthine derivatives of the formula:

20




25

30 wherein R^J, R^K and Q^D are substituted or unsubstituted aliphatic or alicyclic hydrocarbon having 1 to 8 carbon atoms (substituents are selected from halogen, alkyl and hydroxy) or substituted or unsubstituted aromatic hydrocarbon (substituents are selected from halogen, alkyl and hydroxy) or phenethyl.

[0009] EP 203721A (Japanese Published Unexamined Patent Application No. 42986/87) discloses xanthine derivatives of the formula:

35



45

wherein R^L and R^M are alkyl or amino-substituted aralkyl; one of R^N and R^P is hydrogen and the other is -Y^B-Z (wherein Y^B is alkenylene and Z is carboxy). The xanthine derivatives have adenosine antagonistic activity.

[0010] EP-A-0 374 808 discloses xanthine derivatives having adenosine antagonistic activity.

[0011] The object of the invention is to provide novel xanthine derivatives having excellent anti-dementia activity.


50

[0012] This object as well as other objects and advantages of the present invention will become apparent to those skilled in the art from the following description.

[0013] The present invention provides a xanthine derivative of the formula (I) [hereinafter merely referred to as the compound (I)]

55

5



10

wherein either R¹ or R² represents substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, substituted or unsubstituted alicyclic alkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted benzyl; and the other represents -(CH₂)_m-X,
wherein n is 2 or 3, and X is

15


20



25

where a is NH, O or S, and b and d are the same or different and are CH or N,
or


30



35

where e, g and h are the same or different and are CH or N;
Q represents

40



45

(wherein R³ and R⁴ are the same or different and are substituted or unsubstituted alicyclic alkyl),


50



55

(wherein Y is single bond or alkylene; and n is 0 or 1),

5



10 (wherein --- is single or double bond, and Y is the same as defined above), or

15



20 (wherein Y is the same as defined above);

or a pharmacologically acceptable salt thereof.

[0014] In the compound (I), the alkyl moiety in the substituted or unsubstituted lower alkyl represented by R^1 and R^2 is straight or branched chain alkyl having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl or hexyl. Substituents of the lower alkyl are alicyclic alkyl having 3 to 8 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclooctyl. Lower alkenyl is straight or branched chain alkenyl having 2 to 4 carbon atoms such as vinyl, allyl, propenyl, isopropenyl, butenyl, or isobutenyl.

[0015] Lower alkynyl is straight or branched chain alkynyl having 2 to 4 carbon atoms such as propargyl or 3-butynyl.

[0016] The alicyclic alkyl moiety in the substituted or unsubstituted alicyclic alkyl is cycloalkyl having 3 to 8 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclooctyl.

[0017] The alicyclic alkyl, phenyl and benzyl may have 1 to 3 substituents and they are the same or different and are lower alkyl, hydroxy, lower alkoxy, halogen, nitro or amino. The alkyl moieties of the lower alkyl and the lower alkoxy are the same as those described above. The halogen includes fluorine, chlorine, bromine and iodine.

[0018] The alkylene represented by Y is straight or branched chain alkylene having 1 to 4 carbon atoms such as methylene, ethylene, trimethylene, tetramethylene, methylmethylenes, propylene or ethylethylene.


[0019] The pharmacologically acceptable salt of the compound (I) includes pharmacologically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like.

[0020] As the pharmacologically acceptable acid addition salt, there are salts formed with inorganic acids such as hydrochloride, sulfate or phosphate, salts formed with organic acids such as acetate, maleate, fumarate, tartrate or citrate. As the metal salt, there are alkali metal salts such as sodium salt or potassium salt, alkaline earth metal salts such as magnesium salt or calcium salt, aluminum salt and zinc salt. As the ammonium salts, there are ammonium salt, tetramethylammonium salt and the like. As the organic amine addition salt, there are morpholine addition salt, piperidine addition salt and the like. As the amino acid addition salt, there are lysine addition salt, phenylalanine addition salt and the like.

[0021] The present invention provides a xanthine derivative of the formula (I) wherein one of R^1 and R^2 represents unsubstituted straight or branched chain C_{1-6} alkyl; and the other represents


45

50



[0022] The present invention provides further a xanthine derivative of the formula (I) wherein one of R^1 and R^2 represents unsubstituted straight or branched chain C_{1-6} alkyl; and the other represents

55



and wherein Q is



15

[0023] The compound (I) can be produced according to the following reaction scheme:

20

25

30


35


40

45

50


55





or

5



wherein a, b, d, e, g and h are the same as defined above, and P is a protecting group of the amino group; Hal is halogen; and R¹, R² and Q are as defined above.

[0024] As the protecting group, there are tert-butoxycarbonyl, benzyloxycarbonyl, acetyl, formyl and the like. Halogen is the same as defined above.

[0025] Each step is explained below.

15 Step 1

[0026] The compound (IV) is obtained by reacting the compound (II) which can be obtained according to a known method (for example, EP 103497A) with the compound (III) or a reactive derivative thereof.

[0027] As the reactive derivative of the compound (III), for example, there are acid halides such as acid chloride or acid bromide, active esters such as p-nitrophenyl ester or N-oxysuccinimide, acid anhydrides obtained by using carbodiimide such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, diisopropylcarbodiimide or dicyclohexylcarbodiimide, mixed acid anhydrides with monoethyl carbonate ester, monoisobutyl carbonate ester and the like.

[0028] In this reaction, the compound (III) is used in an amount of 1 to 5 equivalents per 1 equivalent of the compound (II).

[0029] When the compound (III) is used, the reaction is carried out by heating to 50 to 200 °C in the absence of a solvent. When the reactive derivative is used, the reaction can be carried out according to a common method in the field of peptide chemistry. For example, the reaction can be carried out in a solvent selected from halogenated hydrocarbons such as methylene chloride, chloroform or ethane dichloride, ethers such as dioxane or tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, if necessary, water and the like. The reaction is carried out at a temperature of -80 to 80 °C and is completed within 0.5 to 24 hours. If necessary, the reaction can be carried out in the presence of an additive such as 1-hydroxybenzotriazole, or a base such as pyridine, triethylamine, 4-dimethylaminopyridine or N-methylmorpholine.

35 Step 2

[0030] The compound (V) is obtained by ring closure reaction of the compound (IV) in the presence of a base (Process A), by treatment with a dehydrating agent (Process B), or by heating (Process C).

40 Process A

[0031] The compound (V) is obtained by reacting the compound (IV) at a temperature of 4 °C to 180 °C for 10 minutes to 6 hours in a solvent in the presence of a base.

[0032] As the base, there are alkali metal hydroxides such as sodium hydroxide or potassium hydroxide. As the solvent, there are water, lower alkanols such as methanol or ethanol, ethers such as dioxane or tetrahydrofuran, dimethylformamide, dimethyl sulfoxide and the like. These solvents can be used alone or in combination thereof.

Process B

[0033] The compound (V) is obtained by reacting the compound (IV) at a temperature of 4 °C to 180 °C for 0.5 to 12 hours in a solvent or without any solvent in the presence of a dehydrating agent.

[0034] As the dehydrating agent, there are thionyl halides such as thionyl chloride, phosphorus oxyhalides such as phosphorus oxychloride. As the solvent, there are halogenated hydrocarbons such as methylene chloride, chloroform or ethane dichloride, dimethylformamide, dimethyl sulfoxide and the like.

55 Process C

[0035] The compound (V) is obtained by heating the compound (IV) at 50 to 200 °C for 1 to 20 hours in a solvent.

[0036] As the solvent, there are dimethylformamide, dimethyl sulfoxide, Dowthermo A (manufactured by Dow Chem-

ical Co., U.S.A.) and the like.

Step 3

5 [0037] The compound (I) is obtained by deprotecting the protecting group P of the compound (V) according to a conventional method employed in the field of synthetic organic chemistry.

[0038] When the protecting group P is, for example, benzyloxycarbonyl group, catalytic hydrogenation is carried out with hydrogen gas in a solvent at an atmospheric pressure in the presence of a hydrogenation catalyst. The reaction is carried out at a temperature of 4 °C to 100 °C for 0.5 to 48 hours.

10 [0039] As the hydrogenation catalyst, there are platinum catalysts such as platinum oxide or activated carbon on platinum (Pt/C), palladium catalysts such as activated carbon on palladium (Pd/C) or palladium black, nickel catalysts such as Raney nickel, activated carbon on rhodium (Rh/C) and the like. As the solvent, there are alcohols such as methanol or ethanol, esters such as ethyl acetate, ethers such as dioxane or tetrahydrofuran, N,N-dimethylformamide, acetic acid and the like.

15 Step 4

20 [0040] The compound (VI) is obtained from the compound (IV) according to the same manner as that described in Step 3.

25 Step 5

30 [0041] The compound (I) is obtained from the compound (VI) according to the same procedure as that described in Step 2.

35 Step 6

35 [0042] The compound (VIII) is obtained by reacting the compound (II) with the compound (VII) at -80 to 100 °C for 10 minutes to 5 hours in a solvent.

[0043] In the reaction, the compound (VII) is used in an amount of 1 to 2 equivalents per 1 equivalent of the compound (II).

[0044] As the solvent, there are mixed solvents of acetic acid with lower alcohols such as methanol or ethanol.

40 Step 7

45 [0045] The compound (V) is obtained by reacting the compound (VIII) at 4 °C to 180 °C for 30 minutes to 10 hours in a solvent in the presence of an oxidizing agent.

[0046] As the oxidizing agent, there are oxygen, ferric chloride, ammonium cerium (IV) nitrate, diethylazodicarboxylate and the like. As the solvent, there are lower alcohols such as methanol or ethanol, halogenated hydrocarbons such as methylene chloride or chloroform, aromatic hydrocarbons such as toluene, xylene or nitrobenzene.

50 Step 8

45 [0047] The compound (XI) is obtained by reacting the compound (X) and the compound (IX) at a temperature of 50 to 150 °C for 30 minutes to 10 hours.

[0048] In the reaction, the compound (X) is used in an amount of 1 to 2 equivalents per 1 equivalent of the compound (IX).

[0049] As the solvent, there are lower alcohols such as methanol or ethanol, dimethylformamide, dimethyl sulfoxide and the like.

55 Step 9

55 [0050] The compound (V) is obtained by reacting the compound (XI) and a nitrosating agent at a temperature of 4 °C to the boiling point of the solvent for 30 minutes to 10 hours in a solvent in the presence of an acid.

[0051] In the reaction, the nitrosating agent is used in an amount of 1 to 3 equivalents per 1 equivalent of the compound (XI).

[0052] As the nitrosating agent, there are nitrous acid derivatives such as sodium nitrite or isoamyl nitrite.

[0053] As the acid, there are acetic acid, dilute hydrochloric acid and the like. As the solvent, there are lower alcohols

such as methanol or ethanol.

Step 10

5 [0054] The compound (I) is obtained from the compound (V) according to the same procedure as that described in Step 3.

[0055] The desired compounds in the above respective steps can be isolated and purified by a conventional purification method usually employed in the field of synthetic organic chemistry such as filtration, extraction, washing, drying, concentration, recrystallization or various chromatographic processes.

10 [0056] The salt of the compound (I) can be obtained by a conventional method usually employed in the field of synthetic organic chemistry. For example, when the compound (I) is obtained in a salt form, it may be purified as it is. When the compound (I) is obtained in the free form, it may be dissolved or suspended in a suitable solvent and thereafter an acid or base may be added thereto to form a salt.

15 [0057] In addition, the compound (I) or pharmacologically acceptable salt thereof may be in an addition form of water or various solvents, and these addition forms are included in the scope of the present invention.

[0058] Further, the compound (I) can exist in the form of optical isomers. The present invention includes all possible stereoisomers or mixture thereof including the optical active isomer.

[0059] The examples of the compound (I) are shown in Table 1.

20

25

30

35

40

45


50

55

Table 1

5

10



15

Compound No.	R ¹	R ²	Q
1	n-C ₃ H ₇	-CH ₂ CH ₂ -C ₆ H ₄ -NH ₂	
2	-CH ₂ CH ₂ -C ₆ H ₄ -NH ₂	n-C ₃ H ₇	
3	n-C ₃ H ₇	-CH ₂ CH ₂ -C ₆ H ₄ -NH ₂	
4	-CH ₂ CH ₂ -C ₆ H ₄ -NH ₂	n-C ₃ H ₇	
5	n-C ₃ H ₇	-CH ₂ CH ₂ -C ₆ H ₄ -NH ₂	
6	n-C ₃ H ₇	-CH ₂ CH ₂ -C ₆ H ₄ -NH ₂	

55

[0060] The pharmacological activity of the compound (I) is illustrated by the following experiment:

Experimental Data

[0061] The effect of Compound (I) on dementia was determined by scopolamine induced amnesia models (Basic Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases; Vol. 2; T. Nagatsu, et al. edt; pp449; Plenum Press New York; 1990).

[0062] Male whister rats (Charles River Laboratories) weighing 220 g to 280 g were used for the test, and each group consisted of 12 to 13 animals. The test was performed with a step-through type passive avoidance apparatus (the bright and dark box).

[0063] The bright and dark box was made up of a bright compartment (25 x 25 x 25 cm) lighted by 4W white luminescent and a dark compartment (25 x 25 x 25 cm). These two compartments were partitioned by a guillotine door (9 x 9 cm) and had a grid floor of stainless steel. In order to give a foot shock, the electric current (2 mA : 2 sec) may be passed through the grid floor of the dark compartment.

[0064] The compound to be tested was suspended in 0.3% aqueous carboxymethyl cellulose solution and the suspension was orally administered 60 minutes before the acquired trial (only 0.3% aqueous carboxymethyl cellulose solution was given to the control group).

[0065] Amnesia treatment was carried out by intraperitoneally administering 1 mg/kg of scopolamine 30 minutes before the following acquired trial.

[0066] The training for acquisition of learning (acquired trial) was carried out. The rat was then introduced into the bright compartment and, after 5 to 10 seconds, the guillotine door was opened. The rat in the bright compartment rapidly moved into the dark compartment. As soon as the whole body of the rat entered into the dark compartment, the guillotine door was closed. An electric current of 2 mA was immediately passed through the grid floor for two seconds (foot shock). After the trial, the rat receiving the foot shock (acquisition of learning) was taken out of the dark compartment.

[0067] A test trial (retention trial) was carried out for observing the retention and recall of the memory, as follows. Twenty-four hours after the acquired trial, the rat was placed in the bright compartment and the guillotine door was opened. The time required from opening of the guillotine door to movement of the rat from the bright compartment into the dark compartment (latency) was measured. The time (latency) was measured up to 600 seconds and the time of over 600 seconds was regarded as 600 seconds.

[0068] In the experiment, the amnesia control group had undergone amnesia treatment and the normal control group had not undergone amnesia treatment.

[0069] Latency of test compound treated group and latency of amnesia control group were compared in Table 2. In Table 2, test of significance was performed by Mann Whitney U-test.

Table 2

Test compound	Dose (mg/kg) p.o.)	Amnesia treatment	Number of animals	Recall trial mean reaction latent time (sec.)	Comparison to amnesia control
Normal control	0	-	10	557.8±232.8	-
Amnesia control	0	+	15	13.5±3.0	*
Compound 1	0.02	+	15	22.9±5.5	not significant
	0.08	+	15	20.5±3.5	not significant
	0.31	+	15	95.9±41.1	p<0.01
	1.25	+	15	136.4±41.9	p<0.001
	5.0	+	15	182.3±57.5	p<0.01
	20.0	+	15	231.4±76.2	p<0.001
Normal control	0	-	13	557.4±21.6	-
Amnesia control	0	+	19	33.8±11.5	*
Compound 3	0.02	+	14	47.7±16.4	not significant
	0.08	+	14	119.2±45.2	p<0.05
	0.31	+	14	152.6±41.7	p<0.001
	1.25	+	14	70.8±41.7	not significant

* Latency of amnesia control group is significantly lower than latency of normal control, (p<0.001).

Table 2 (continued)

Test compound	Dose (mg/kg) p.o.)	Amnesia treatment	Number of animals	Recall trial mean reaction latent time (sec.)	Comparison to amnesia control
	5.0	+	14	66.9±33.8	not significant
Normal control	0	-	13	557.4±21.6	-
Amnesia control	0	+	20	44.2±10.8	*
Compound 4	0.02 0.08 0.31 1.25 5.0	+	15 15 15 15 15	117.7±38.2 216.9±57.9 106.5±40.9 199.5±64.0 105.3±31.8	p<0.05 p<0.01 not significant p<0.05 p<0.05

* Latency of amnesia control group is significantly lower than latency of normal control, ($p<0.001$).

Acute toxicity test:

[0070] The compound 1, 2, 3 and 4 were orally administered to dd strain male mice (body weight: 20 ± 1 g, 3 mice/group). The lethal state was observed 7 days after administration to obtain the minimum lethal dose (MLD).

[0071] MLD of the all compounds were >300 mg/kg. This is weak toxicity and therefore the compound can be used safely in a wide dose range.

[0072] The compound (I) or a pharmacologically acceptable salt thereof can be used as it is or in various pharmaceutical composition forms.

[0073] The pharmaceutical composition of the present invention can be prepared by uniformly mixing an effective amount of the compound (I) or a pharmacologically acceptable salt thereof as an active component with a pharmaceutically acceptable carrier. The pharmaceutical composition are preferably in the form of a unit dosage form suitable for oral administration or injection.

[0074] For preparing A pharmaceutical composition for oral administration, any useful pharmaceutically acceptable carrier or diluent can be used. For example, suspensions and syrups can be prepared using water, sugars such as sucrose, sorbitol or fructose, glycols such as polyethylene glycol or propylene glycol, oils such as sesame oil, olive oil or soybean oil, preservatives such as p-hydroxybenzoic acid esters flavors such as strawberry flavor or peppermint.

[0075] Powders, pills, capsules and tablets can be prepared using excipients such as lactose, glucose, sucrose or mannitol, disintegrating agents such as starch or sodium alginate lubricants such as magnesium stearate or talc, binders such as polyvinyl alcohol, hydroxypropyl cellulose or gelatin, surfactants such as fatty acid esters plasticizers such as glycerin. Tablets and capsules are most useful oral unit dosage forms because of easy administration.

[0076] Injectable preparations can be prepared using a carrier such as distilled water, a salt solution, glucose solution or mixture of a salt solution and glucose solution. The preparations can be prepared in the form of solutions, suspensions or dispersions by using a suitable method.

[0077] The compound (I) or a pharmacologically acceptable salt thereof can be used to be administered orally in the said dosages forms or parenterally as injections. The effective dosage regimen and administration route vary depending upon a particular dosage form and particular age, weight and conditions of the patient. However, normally, the compound (I) or a pharmacologically acceptable salt thereof is to be administered in the amount of 0.02 to 50 mg/kg per day and the dosage can be divided to be administered 3 to 4 times per day.

[0078] The following Examples and Reference Examples further illustrate the present invention in detail but are not to be construed to limit the scope thereof.

Example 1

[0079] 3-Noradamantanecarboxylic acid (2.79 g, 16.8 mmol) was dissolved in a mixture of tetrahydrofuran (50 ml) and methylene chloride (50 ml). 1-Hydroxybenzotriazole (2.57 g, 16.8 mmol) and 1-ethyl-3-(3-dimethylamino)propyl-carbodiimide hydrochloride (3.22 g, 16.8 mmol) were added at 0°C , and reacted at room temperature for 4 hours. To the resulting solution, 4-dimethylaminopyridine (170 mg, 1.4 mmol); followed by a solution of 5,6-diamino-1-(4-benzoyloxycarbonylaminophenethyl)-3-propyluracil (6.12 g, 14.0 mmol; obtained in Reference Example 1) in a mixture of N,N-dimethylformamide (20 ml) and tetrahydrofuran (40 ml) were added. After reacting for one hour, the reaction mixture was concentrated by reducing the volume in halves. After the addition of water (100 ml) to the concentrated mixture,

EP 0 541 120 B1

the mixture was extracted three times with chloroform. The organic layers were combined, washed with an aqueous saturated solution of sodium chloride, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was isolated and purified by silica gel column chromatography (eluent: 2% methanol/98% chloroform) to obtain 6-amino-5-(3-noradamantane)carbonylamino-1-(4-benzyloxycarbonylaminophenethyl)-3-propyluracil (6.95 g, yield: 85%).

NMR (90MHz; CDCl₃) δ(ppm): 7.99 (1H, brs), 7.50-7.25 (7H, m), 7.12 (2H, d, J=7.8Hz), 6.89 (1H, brs), 5.20 (2H, s), 4.25-3.65 (6H, m), 3.05-2.75 (3H, m), 2.45-1.45 (14H, m), 0.90 (3H, t, J=7.0Hz)

[0080] The resulting compound (6.81 g, 11.6 mmol) was dissolved in ethanol (200 ml) and the catalyst 10% Pd/C (600 mg) was added thereto. The mixture was stirred for 15 hours under hydrogen. The catalyst was removed by filtration, washed with ethanol and the filtrate was concentrated. The residue was purified on silica gel column chromatography (eluent: 5% methanol/95% chloroform) and triturated with diethyl ether/hexane=3/1 (v/v) to obtain 6-amino-1-(4-aminophenethyl)-5-(3-noradamantane)carbonylamino-3-propyluracil (3.65 g, yield: 69%).

NMR (90MHz; CDCl₃) δ(ppm): 7.32 (1H, brs), 6.97 (2H, d, J=8.5Hz), 6.60 (2H, d, J=8.5Hz), 5.28 (2H, brs), 4.20-3.75 (4H, m), 3.27 (2H, brs), 3.00-2.75 (3H, m), 2.45-1.45 (14H, m), 0.96 (3H, t, J=7.0Hz)

[0081] The resulting compound (3.50 g, 7.75 mmol) was dissolved in dioxane (80 ml). 1N Aqueous solution (240 ml) of sodium hydroxide was added thereto. The mixture was heated under reflux for 1 hour. After cooling, the solution was neutralized with conc. hydrochloric acid, and the precipitated crystals were filtered, dried under reduced pressure and recrystallized from tetrahydrofuran to obtain 3-(4-aminophenethyl)-8-(3-noradamantyl)-1-propylxanthine (compound 1) (1.33 g, yield: 40%).

Melting point: 283.7-285.2 °C

Elementary analysis for C₂₅H₃₁N₅O₂,

Calc. (%): C 69.25, H 7.20, N 16.15

Found (%): C 69.38, H 7.48, N 16.17

IR (KBr) ν_{max} (cm⁻¹): 1694, 1644, 1554, 1519, 1494

NMR (270MHz; DMSO-d₆) δ(ppm): 13.0 (1H, brs), 6.83 (2H, d, J=8.4Hz), 6.46 (2H, d, J=8.4Hz), 4.86 (2H, brs), 4.10 (2H, t, J=7.4Hz), 3.83 (2H, t, J=7.4Hz), 2.78 (2H, t, J=7.4Hz), 2.61 (1H, t, J=6.5Hz), 2.35-2.25 (2H, m), 2.20-2.10 (2H, m), 2.00-1.85 (4H, m), 1.70-1.50 (6H, m), 0.86 (3H, t, J=8.0Hz)

MS (m/e): 433 (M⁺)

Example 2

[0082] 1-(4-Aminophenethyl)-8-(3-noradamantyl)-3-propylxanthine (compound 2, 0.32 g) was obtained (yield: 37%) according to the same manner as that described in Example 1, except that 3-noradamantanecarboxylic acid (0.40 g, 2.41 mmol) and 5,6-diamino-3-(4-benzyloxycarbonylaminophenethyl)-1-propyluracil (0.8? g, 2.01 mmol) obtained in Reference Example 2 were used instead of 3-noradamantanecarboxylic acid (2.79 g, 16.8 mmol) and 5,6-diamino-1-(4-benzyloxycarbonylaminophenethyl)-3-propyluracil (6.12 g, 14.0 mmol) obtained in Reference Example 1.

Melting point: 244.6-245.1°C

Elementary analysis for C₂₅H₃₁N₅O₂,

Calc. (%): C 69.25, H 7.20, N 16.15

Found (%): C 69.06, H 7.26, N 15.95

IR (KBr) ν_{max} (cm⁻¹): 1694, 1657, 1645, 1547, 1518, 1493

NMR (270MHz; DMSO-d₆) δ(ppm): 12.92 (1H, brs), 6.87 (2H, d, J=7.9Hz), 6.48 (2H, d, J=7.9Hz), 4.87 (2H, brs), 3.99 (2H, t, J=7.9Hz), 3.95 (2H, t, J=7.4Hz), 2.65-2.55 (3H, m), 2.30-2.25 (2H, m), 2.20-2.10 (2H, m), 2.00-1.85 (4H, m), 1.75-1.55 (6H, m), 0.87 (3H, t, J=7.4Hz)

MS (m/e): 433 (M⁺)

Example 3

[0083] 3-(4-Aminophenethyl)-8-dicyclopropylmethyl-1-propylxanthine (compound 3, 0.28 g) was obtained (yield: 13%) according to the same manner as that described in Example 1 except that dicyclopropylacetic acid (1.12 g, 8.0 mmol) and 5,6-diamino-1-(4-benzyloxycarbonylaminophenethyl)-3-propyluracil (2.93 g, 8.0 mmol) obtained in Reference Example 1 were used instead of 3-noradamantanecarboxylic acid (2.79 g, 16.8 mmol) and 5,6-diamino-1-(4-ben-

EP 0 541 120 B1

zyloxy carbonylaminophenethyl)-3-propyluracil (6.12 g, 14.0 mmol) obtained in Reference Example 1.

Melting point: 184.7-184.9°C

Elementary analysis for C₂₃H₂₉N₅O₂:

Calc. (%): C 67.78, H 7.17, N 17.19

Found (%): C 67.95, H 7.37, N 16.97

IR (KBr) ν_{max} (cm⁻¹): 1693, 1646, 1552, 1517, 1495

NMR (270MHz; DMSO-d₆) δ(ppm): 13.06 (1H, brs), 6.83 (2H, d, J=8.3Hz), 6.46 (2H, d, J=8.3Hz), 4.84 (2H, brs), 4.11 (2H, t, J=7.1Hz), 3.83 (2H, t, J=6.9Hz), 2.79 (2H, t, J=7.9Hz), 1.60-1.45 (3H, m), 1.30-1.15 (2H, m), 0.86 (3H, t, J=7.4Hz), 0.65-0.50 (2H, m), 0.40-0.25 (4H, m), 0.25-0.10 (2H, m)

MS (m/e): 407 (M⁺)

Example 4

[0084] 1-(4-Aminophenethyl)-8-dicyclopropylmethyl-3-propylxanthine (compound 4, 0.25 g) was obtained (yield: 20%) according to the same procedure as that described in Example 1, except that dicyclopropylacetic acid (0.73 g, 5.2 mmol) and 5,6-diamino-3-(4-benzyloxycarbonylaminophenethyl)-1-propyluracil (1.71g, 4.67 mmol) obtained in Reference Example 2 were used instead of 3-noradamantanecarboxylic acid (2.79 g, 16.8 mmol) and 5,6-diamino-1-(4-benzyloxycarbonylaminophenethyl)-3-propyluracil (6.12 g, 14.0 mmol) obtained in Reference Example 1, respectively.

Melting point: 190.7-193.2°C

Elementary analysis for C₂₃H₂₉N₅O₂:

Calc. (%): C 67.78, H 7.17, N 17.19

Found (%): C 67.67, H 7.35, N 16.93

IR (KBr) ν_{max} (cm⁻¹): 1694, 1652, 1532, 1516, 1496

NMR (270MHz; DMSO-d₆) δ(ppm): 13.08 (1H, brs), 6.87 (2H, d, J=8.5Hz), 6.48 (2H, d, J=8.5Hz), 4.86 (2H, brs), 4.10-3.90 (2H, t, J=7.9Hz), 1.75-1.50 (3H, m), 1.30-1.15 (2H, m), 0.87 (3H, t, J=7.4Hz), 0.60-0.50 (2H, m), 0.40-0.25 (4H, m), 0.20-0.10 (2H, m)

MS (m/e): 407 (M⁺)

Example 5

[0085] 3-(4-Aminophenethyl)-8-[(1R*, 2R*, 5R*)-bicycle[3.3.0]octan-2-yl]-1-propylxanthine (Compound 5, 1.48 g) was obtained (yield: 25%) according to the same procedure as that described in Example 1, except that bicyclo[3.3.0]octane-2-carboxylic acid (1.70g, 11.0 mmol) and 5,6-diamino-1-(4-benzyloxycarbonylaminophenethyl)-3-propyluracil (4.00 g, 9.14 mmol) obtained in Reference Example 1 were used instead of 3-noradamantanecarboxylic acid (2.79 g, 16.8 mmol) and 5,6-diamino-1-(4-benzyloxycarbonylaminophenethyl)-3-propyluracil (6.12 g, 14.0 mmol) obtained in Reference Example 1.

Melting point: 237.1-238.1°C

Elementary analysis for C₂₄H₃₁N₅O₂:

Calc. (%): C 68.38, H 7.41, N 16.61

Found (%): C 68.09, H 7.67, N 16.58

IR (KBr) ν_{max} (cm⁻¹): 1700, 1641, 1554, 1505

NMR (270MHz; CDCl₃) δ(ppm): 12.27, (1H, brs), 7.08 (2H, d, J=8.4Hz), 6.61 (2H, d, J=8.4Hz), 4.31 (2H, t, J=7.9Hz), 4.01 (2H, t, J=7.8Hz), 3.57 (2H, brs), 2.97 (2H, t, J=7.9Hz), 2.90-2.65 (3H, m), 2.20-1.25 (12H, m), 0.97 (3H, t, J=7.3Hz)

MS (m/e): 421 (M⁺)

50

Example 6

[0086] 3-(4-Aminophenethyl)-8-[(1R*, 2S*, 5S*)bicyclo[2.2.1]heptan-2-yl]-3-propylxanthine and (1R*, 2R*, 5S*)isomer (1:1 mixture) (Compound 6, 1.47 g) was obtained (yield: 40%) according to the same procedure as that described in Example 1, except that bicyclo[2.2.1]heptane-2-carboxylic acid (1.54 g, 11.0 mmol) and 5,6-diamino-1-(4-benzyloxycarbonylaminophenethyl)-3-propyluracil (4.0 g, 9.14 mmol) obtained in Reference Example 1 were used instead of 3-noradamantanecarboxylic acid (2.79 g, 16.8 mmol) and 5,6-diamino-1-(4-benzyloxycarbonylaminophenethyl)-3-propyluracil (6.12 g, 14.0 mmol) obtained in Reference Example 1.

EP 0 541 120 B1

Melting point : 258.3-260.2°C

IR (KBr) ν_{\max} (cm⁻¹): 1704, 1649, 1520, 1496

NMR (270MHz; DMSO) δ(ppm): 12.99 (1H, brs), 6.83 (2x1/2H, d, J=8.4Hz), 6.82 (2x1/2H, d, J=8.4Hz), 6.45 (2H, d, J=8.4Hz), 4.86 (2H, brs), 4.11 (2x1/2H, t, J=7.4Hz), 4.09 (2x1/2H, t, J=7.4Hz), 3.81 (2H, t, J=7.0Hz), 3.25-3.15 (1/2H, m), 2.80-2.70 (1/2H+2H, m), 2.60-2.25 (2H, m), 2.10-1.10 (10H, m), 0.85 (3H, t, J=7.4Hz)

MS (m/e): 407 (M⁺)

Reference Example 1

[0087] 4-Nitrophenethylamine (127 g, 0.767 mol) [J. Org. Chem., 43, 31(1978)] was dissolved in toluene (2.5 liters), and propyl isocyanate (72 ml, 0.764 mol) was slowly added dropwise to the solution at room temperature. After stirring for 2 hours, the crystals formed were collected and dried under reduced pressure to obtain 1-(4-nitrophenethyl)-3-propylurea [compound (a)] (171.5 g, yield: 89.8%).

IR (KBr) ν_{\max} (cm⁻¹): 3322, 2870, 1620, 1578, 1516

NMR (CDCl₃, 90MHz) δ(ppm): 8.10 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.8Hz), 4.95-4.50 (2H, m), 3.70-3.30 (2H, m), 3.25-2.75 (6H, m), 1.70-1.30 (2H, m), 0.90 (3H, t, J=7.0Hz)

[0088] The compound (a) (170 g, 0.677 mol) and cyanoacetic acid (63.3 g, 0.744 mol) were dissolved in acetic anhydride (196 ml) and reacted at 75°C for 2 hours. The reaction mixture was concentrated under reduced pressure, water (200 ml) was added thereto and the mixture was concentrated again under reduced pressure. The resulting crude crystals were recrystallized twice from ethyl acetate to give 1-cyanoacetyl-3-(4-nitrophenethyl)-1-propylurea [compound (b)] (42.9 g, yield: 19.9%). The filtrate obtained from recrystallization was concentrated under reduced pressure and the residue was purified on silica gel column chromatography (eluent: 2% methanol/98% chloroform) to give the compound (b) (62.2 g, yield 29%) and 1-cyanoacetyl-1-(4-nitrophenethyl)-3-propylurea [compound (c)] (45.0 g, yield: 21%).

Compound (b):

[0089]

IR (KBr) ν_{\max} (cm⁻¹): 3386, 2876, 2260, 1693, 1678, 1518, 1503

NMR (CDCl₃, 90MHz) δ(ppm): 8.55 (1H, brs), 8.16 (2H, d, J=8.7Hz), 7.38 (2H, d, J=8.7Hz), 3.78 (2H, s), 3.80-3.45 (4H, m), 3.01 (2H, t, J=7.0Hz), 1.80-1.40 (2H, m), 0.99 (3H, t, J=7.0Hz)

MS (m/e): 318 (M⁺)

Compound (c):

NMR (90MHz; CDCl₃) δ(ppm): 8.17 (2H, d, J=8.5Hz), 7.36 (2H, d, J=8.5Hz), 3.90 (2H, t, J=7.5Hz), 3.63 (2H, s), 3.40-3.00 (4H, m), 1.61 (2H, s), 1.80-1.40 (2H, m), 0.96 (3H, t, J=7.0Hz)

2N Aqueous solution (680 ml) of sodium hydroxide was added to the resulting compound (b) (57.5 g, 0.181 mol) and the mixture was stirred at 75°C for 30 minutes. After cooling, the resulting crystals were collected, washed with water and dried under reduced pressure to obtain 6-amino-1-(4-nitrophenethyl)-3-propyluracil [compound (d)] (51.7 g, yield: 89.7%).

IR (KBr) ν_{\max} (cm⁻¹): 1658, 1639, 1611, 1518, 1492

NMR (90MHz; DMSO-d₆) δ(ppm): 8.10 (2H, d, J=8.5Hz), 7.47 (2H, d, J=8.5Hz), 6.82 (2H, brs), 4.78 (1H, s), 4.08 (2H, t, J=7.2Hz), 1.65-1.15 (2H, m), 0.77 (3H, t, J=7Hz)

MS (m/e): 318 (M⁺)

[0090] The compound (d) (20 g, 62.8 mmol) was dissolved in acetic acid (100 ml) and 10% Pd/C (1g) was added thereto. The mixture was stirred for 8 hours under hydrogen. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure and made alkaline by the addition of 1N aqueous solution of sodium hydroxide. The precipitated crystals were collected by filtration, washed with water and dried under reduced pressure to obtain 6-amino-1-(4-aminophenethyl)-3-propyluracil [compound (e)] (15.6 g, yield: 86.5%).

IR (KBr) ν_{\max} (cm⁻¹): 1658, 1613, 1517

NMR (90MHz; CDCl₃) δ(ppm): 7.00 (2H, d, J=8.0Hz), 6.67 (2H, d, J=8.0Hz), 4.82 (1H, s), 4.20-3.70 (6H, m), 2.90 (2H, t, J=7.5Hz), 1.80-1.50 (4H, m), 0.95 (3H, t, J=7.2Hz)

MS (m/e): 288 (M⁺)

EP 0 541 120 B1

[0091] The compound (e) (7 g, 24.3 mmol) was dissolved in tetrahydrofuran (180 ml) and water (120 ml) and sodium bicarbonate (4.13 g, 49.2 mmol) were added thereto. This solution was cooled to 5 to 10°C, and 30% solution (11.9 g, 20.8 mmol) of carbobenzoxy chloride in toluene was added dropwise thereto while maintaining pH at 8 to 9 with 2N aqueous solution of sodium hydroxide. The mixture was then stirred for 30 minutes and concentrated under reduced pressure. Water was added thereto and the precipitate was collected. The precipitate was dissolved in ethyl acetate (500 ml) by heating and the solution was dried over sodium sulfate and then the solvent was evaporated under reduced pressure to obtain 6-amino-1-(4-benzyloxycarbonylaminophenethyl)-3-propyluracil [compound (f)] (10.0 g, yield: 98.0%).

10 IR (KBr) ν_{max} (cm⁻¹): 1706, 1660, 1606, 1527, 1511
NMR (90MHz; DMSO-d₆) δ(ppm): 8.63 (1H, brs), 7.65-7.20 (7H, m), 7.11 (2H, d, J=8.5Hz), 5.15 (2H, s), 4.67 (1H, s), 3.99 (2H, t, J=7.0Hz), 3.62 (2H, t, J=7.5Hz), 2.73 (2H, t, J=7.0Hz), 1.55-1.25 (2H, m), 0.78 (3H, t, J=7.5Hz)
MS (m/e): 422 (M⁺)

15 [0092] The compound (f) (6.3 g, 14.0 mmol) was dissolved in a mixture of ethanol (120 ml) and water (40 ml) and conc. hydrochloric acid (2.87 ml) was added thereto at 30°C, followed by sodium nitrite (1.82 g, 26.4 mmol). After stirring for about 30 minutes, the precipitated purplish red crystals were collected, washed with water and dried under reduced pressure to obtain 6-amino-1-(4-benzyloxycarbonylaminophenethyl)-5-nitroso-3-propyluracil [compound (g)] (8.66g, yield: 82.3%).

20 Melting point: 192.5-194.5°C
IR (KBr) ν_{max} (cm⁻¹): 1730, 1670, 1642, 1527, 1515
NMR (90MHz; DMSO-d₆) δ(ppm): 9.62 (1H, brs), 7.45-7.20 (7H, m), 7.08 (2H, d, J=8.8Hz), 5.12 (2H, s), 4.06 (2H, t, J=7.5Hz), 3.79 (2H, t, J=7.0Hz), 2.75 (2H, t, J=7.5Hz), 1.70-1.25 (2H, m), 0.84 (3H, t, J=7.0Hz)
25 MS (m/e): 451 (M⁺)

30 [0093] The compound (g) (6.3 g, 14.0 mmol) was suspended in 50% aqueous solution (280 ml) of ethanol, and sodium hydrosulfite (9.7 g, 55.7 mmol) was added slowly thereto with stirring over 30 minutes. After insoluble materials were removed by filtration, the filtrate was concentrated under reduced pressure. The resulting crystals were collected, washed with water and dried under reduced pressure to obtain 5,6-diamino-1-(4-benzyloxycarbonylaminophenethyl)-3-propyluracil (5.23 g, yield: 85.7%).

MS (m/e): 437 (M⁺)

35 Reference Example 2

[0094] 2N Aqueous solution (680 ml) of sodium hydroxide was added to the compound (c) (25.3 g, 79.6 mmol). The mixture was stirred at 75°C for 30 minutes. The mixture was cooled, the precipitated crystals were filtered off, washed with water and dried under reduced pressure to obtain 6-amino-3-(4-nitrophenethyl)-1-propyluracil [compound (h)] (20.0 g, yield: 70%).

40 IR (KBr) ν_{max} (cm⁻¹): 1658, 1643, 1608, 1585, 1516, 1344
NMR (90MHz; DMSO-d₆) δ(ppm): 8.50 (2H, d, J=8.5Hz), 7.48 (2H, d, J=8.5Hz), 6.81 (2H, brs), 4.67 (1H, s), 4.00 (2H, t, J=7.3Hz), 3.72 (2H, t, J=7.5Hz), 2.93 (2H, t, J=7.5Hz), 1.70-1.20 (2H, m), 0.81 (3H, t, J=7.0Hz)
45 MS (m/e): 318 (M⁺)

6-Amino-3-(4-aminophenethyl)-1-propyluracil [compound (i)] (9.78 g, yield: 100%) was obtained using the compound (h) (10.8 g, 32.9 mmol) according to the same procedure as that described in Reference Example 1 for obtaining the compound (e) from the compound (d).

IR (KBr) ν_{max} (cm⁻¹): 1686, 1608, 1516, 1494
50 NMR (90MHz; DMSO-d₆) δ(ppm): 6.78 (2H, d, J=8.0Hz), 6.78 (2H, brs), 6.45 (2H, d, J=8.0Hz), 4.78 (2H, brs), 3.93-3.50 (4H, m), 2.65-2.40 (2H, m), 1.70-1.20 (2H, m), 0.86 (3H, t, J=7.0Hz)
MS (m/e): 288 (M⁺)

55 6-Amino-3-(4-benzyloxycarbonylaminophenethyl)-1-propyluracil [compound (j)] (13.25 g, yield: 95%) was obtained using the compound (i) (9.78 g, 33.9 mmol) according to the same procedure as that described in Reference Example 1 for obtaining the compound (f) from the compound (e).

IR (KBr) ν_{max} (cm⁻¹): 1722, 1689, 1657, 1651, 1614, 1525
NMR (90MHz; DMSO-d₆) δ(ppm): 9.62 (1H, s), 7.50-7.15 (7H, m), 7.00 (2H, d, J=9Hz), 6.63 (2H, brs), 5.08 (2H, s), 3.95-3.50 (4H, m), 2.65 (2H, t, J=7.5Hz), 1.70-1.20 (2H, m), 0.86 (3H, t, J=7.0Hz)

MS (m/e): 422 (M⁺)

6-Amino-3-(4-benzyloxycarbonylaminophenethyl)-5-nitroso-1-propyluracil [compound (K)] (12.2 g, yield 87%) was obtained using the compound (j) (13.2 g, 31.1 mmol) according to the same manner as that described in Reference Example 1 for obtaining the compound (g) from the compound (f).

5 IR (KBr) ν_{max} (cm⁻¹): 1720, 1704, 1650, 1640, 1542, 1527


MS (m/e): 451(M⁺)

5,6-Diamino-3-(4-benzyloxycarbonylaminophenethyl)-1-propyluracil (0.8 g, yield 83%) was obtained using the compound (k) (1 g, 2.21 mmol) according to the same manner as that described in Reference Example 1 for obtaining the end compound from the compound (g).

10 MS (m/e): 437 (M⁺)

Claims


15 1. A xanthine derivative of the formula (I):



wherein one of R¹ and R² represents substituted or unsubstituted straight or branched chain C₁₋₆ alkyl, wherein the substituents are alicyclic C₃₋₈ alkyl, straight or branched chain C₂₋₄ alkenyl, straight or branched chain C₂₋₄ alkynyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted benzyl, wherein the substituents of the C₃₋₈ cycloalkyl, phenyl, or benzyl are 1 to 3, are the same or different, and are straight or branched chain C₁₋₆ alkyl, hydroxy, straight or branched chain C₁₋₆ alkoxy, halogen, nitro or amino; and the other represents


35 -(CH₂)_m-X

wherein m is 2 or 3, and X is



where a is NH, O or S, and b and d are the same or different and are CH or N or


50



EP 0 541 120 B1

where e, g and h are the same or different and are CH or N;
 Q represents


5



10

(wherein R³ and R⁴ are the same or different and are substituted or unsubstituted C₃₋₈ cycloalkyl, wherein the substituents are 1 to 3, are the same or different, and are straight or branched chain C₁₋₆ alkyl, hydroxy, straight or branched chain C₁₋₆ alkoxy, halogen, nitro or amino),


15



20

(wherein Y is single bond or straight or branched C₁₋₄ alkylene; and n is 0 or 1),

25



30

(wherein — is single or double bond, and Y is the same as defined above), or

35




40

(wherein Y is the same as defined above); or a pharmacologically acceptable salt thereof.

45

2. The xanthine compound according to claim 1, wherein one of R¹ and R² represents unsubstituted straight or branched chain C₁₋₆ alkyl; and the other represents


50



55

3. The xanthine compound according to claim 2, wherein Q is

5




10 4. The compound according to any one of claims 1 to 3, wherein said salt is selected from the group consisting of acid addition salts, metal salts, ammonium salts, organic amine addition salts and amino acid addition salts.

15 5. A pharmaceutical composition comprising a pharmacologically acceptable carrier and, as an active ingredient, an effective amount of the derivative as defined by any one of claims 1 to 4.

6. A xanthine derivative of the formula (V):

20




25

30 wherein R¹ represents substituted or unsubstituted straight or branched chain C₁₋₆ alkyl, wherein the substituents are alicyclic C₃₋₈ alkyl, straight or branched chain C₂₋₄ alkenyl, straight or branched chain C₂₋₄ alkynyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted benzyl, wherein the substituents of C₃₋₈ cycloalkyl, phenyl, or benzyl are 1 to 3, are the same or different, and are straight or branched chain C₁₋₆ alkyl, hydroxy, straight or branched chain C₁₋₆ alkoxy, halogen, nitro or amino;

35 R² represents -(CH₂)_m-X, wherein m is 2 or 3, and X is


40



45

wherein a is NH, O or S, b and d are the same or different and are CH or N, or

50




55

wherein e, g and h are the same or different and CH or N;


Q represents

5



(wherein R³ and R⁴ are the same or different and are substituted or unsubstituted C₃₋₆ cycloalkyl, wherein the substituents are 1 to 3, are the same or different, and are straight or branched chain C₁₋₆ alkyl, hydroxy, straight or branched chain C₁₋₆ alkoxy, halogen, nitro or amino),

15



20

(wherein Y is single bond or straight or C₁₋₄ alkylene; and n is 0 or 1),

25



30

(wherein --- is single or double bond, and Y is the same as defined above), or

35




40

(wherein Y is the same as defined above).

7. The xanthine compound according to claim 6, wherein R¹ represents unsubstituted straight or branched chain C₁₋₆ alkyl; and the R² represents

45




50

8. The xanthine compound according to claim 7, wherein Q is

55

5




10 Patentansprüche

1. Xanthinderivat der Formel (I):


15

20



25 in der ein Rest von R¹ und R² einen substituierten oder unsubstituierten, unverzweigten oder verzweigten C₁₋₆-Alkylrest bedeutet, wobei die Substituenten alicyclische C₃₋₈-Alkylreste, unverzweigte oder verzweigte C₂₋₄-Alkenylreste, unverzweigte oder verzweigte C₂₋₄-Alkinylreste, substituierte oder unsubstituierte C₃₋₈-Cycloalkylreste, substituierte oder unsubstituierte Phenylreste oder substituierte oder unsubstituierte Benzylreste sind, wobei die C₃₋₈-Cycloalkyl-, Phenyl- oder Benzylreste 1 bis 3 Substituenten aufweisen, die gleich oder verschieden und verzweigte oder unverzweigte C₁₋₆-Alkylreste, eine Hydroxygruppe, unverzweigte oder verzweigte C₁₋₆-Alkoxyreste, ein Halogenatom, eine Nitro- oder Aminogruppe sind, und der andere


30



35

bedeutet, wobei m 2 oder 3 ist, und X eine der folgenden Formeln aufweist


40



45

in der a die Bedeutung NH, O oder S hat, und b und d gleich oder verschieden sind und CH oder N bedeuten, oder


50



55

wobei e, g und h gleich oder verschieden sind und CH oder N bedeuten, der Rest Q eine der folgenden Formeln aufweist

5



(wobei R³ und R⁴ gleich oder verschieden sind und substituierte oder unsubstituierte C₃₋₈-Cycloalkylreste bedeuten, wobei die Anzahl der Substituenten 1 bis 3 ist, diese gleich oder verschieden sind und unverzweigte oder verzweigte C₁₋₆-Alkylreste, eine Hydroxygruppe, unverzweigte oder verzweigte C₁₋₆-Alkoxyreste, ein Halogenatom, eine Nitro- oder Aminogruppe bedeuten), oder

15



20

(wobei Y eine einfache Bindung oder ein unverzweigter oder verzweigter C₁₋₄-Alkylenrest ist und n 0 oder 1 ist), oder

25



30

(wobei --- eine einfache Bindung oder eine Doppelbindung bedeutet und Y wie oben definiert ist), oder

35




40

(wobei Y wie oben definiert ist);
oder dessen pharmazeutisch verträgliches Salz.

45

2. Xanthinverbindung nach Anspruch 1, in der ein Rest von R¹ und R² ein unsubstituierter, unverzweigter oder verzweigter C₁₋₆-Alkylrest bedeutet, und der andere


50



bedeutet.

55 3. Xanthinverbindung nach Anspruch 2, in der Q

5




bedeutet.

10

4. Verbindung nach einem der Ansprüche 1 bis 3, wobei das Salz ausgewählt ist aus Säureadditionssalzen, Metallsalzen, Ammoniumsalzen, organischen Aminen als Additionssalze und Aminosäuren als Additionssalze.
5. Arzneimittel umfassend einen pharmazeutisch verträglichen Träger und als Wirkstoff eine wirksame Menge des Derivats nach einem der Ansprüche 1 bis 4.
6. Xanthinderivat der Formel (V):


20



25

30 in der R¹ substituierte oder unsubstituierte, unverzweigte oder verzweigte C₁₋₆-Alkylreste bedeutet, wobei die Substituenten alicyclische C₃₋₈-Alkyreste, unverzweigte oder verzweigte C₂₋₄-Alkenylreste, unverzweigte oder verzweigte C₂₋₄-Alkinylreste, substituierte oder unsubstituierte C₃₋₈-Cycloalkylreste, substituierte oder unsubstituierte Phenylreste oder substituierte oder unsubstituierte Benzylreste sind, wobei die C₃₋₈-Cycloalkyl-, Phenyl- oder Benzylreste 1 bis 3 Substituenten aufweisen, die gleich oder verschieden und verzweigte oder unverzweigte C₁₋₆-Alkylreste, eine Hydroxygruppe, unverzweigte oder verzweigte C₁₋₆-Alkoxyreste, ein Halogenatom, eine Nitro- oder Aminogruppe sind,
35 und R² den Rest -(CH₂)_m-X bedeutet, wobei m 2 oder 3 ist, und X eine der folgenden Formeln aufweist


40



45

wobei a die Bedeutung NH, O oder S hat, b und d gleich oder verschieden sind und CH oder N bedeuten, oder


50



55

wobei e, g und h gleich oder verschieden sind und CH oder N bedeuten;
der Rest Q eine der folgenden Formeln aufweist

5



10

(wobei R³ und R⁴ gleich oder verschieden sind und substituierte oder unsubstituierte C₃₋₈-Cycloalkylreste bedeuten, wobei die Anzahl der Substituenten 1 bis 3 ist, diese gleich oder verschieden sind und unverzweigte oder verzweigte C₁₋₆-Alkylreste, eine Hydroxygruppe, unverzweigte oder verzweigte C₁₋₆-Alkoxyreste, ein Halogenatom, eine Nitro- oder Aminogruppe bedeuten), oder

15



20

(wobei Y eine einfache Bindung oder ein unverzweigter oder verzweigter C₁₋₄-Alkylenrest ist und n 0 oder 1 ist), oder

25



30

(wobei --- eine einfache Bindung oder eine Doppelbindung bedeutet, und Y wie oben definiert ist), oder

35



40

7. Xanthinverbindung nach Anspruch 6, in der R¹ einen unsubstituierten, unverzweigten oder verzweigten C₁₋₆-Alkylrest bedeutet, und R²

45




50

bedeutet.

55

8. Xanthinverbindung nach Anspruch 7, in der Q

5




10 bedeutet.

Revendications

15 1. Dérivé de xanthine de la formule (I) :

20




25

dans laquelle :

- 30 - l'un parmi R^1 et R^2 représente alkyle en C_{1-6} à chaîne droite ou ramifiée, substitué ou non substitué, dans lequel les substituants représentent alkyle en C_{3-8} alicyclique, alcényle en C_{2-4} à chaîne droite ou ramifiée, alcynyle en C_{2-4} à chaîne droite ou ramifiée, cycloalkyle en C_{3-8} substitué ou non substitué, phényle substitué ou non substitué, ou benzyle substitué ou non substitué, dans lequel les substituants du cycloalkyle en C_{3-8} , du phényle ou du benzyle sont de 1 à 3, sont identiques ou différents, et représentent alkyle en C_{1-6} à chaîne droite ou ramifiée, hydroxy, alcoxy en C_{1-6} à chaîne droite ou ramifiée, halogène, nitro ou amino ; et
- 35 - l'autre représente :

35




40

où :

45

- m vaut 2 ou 3 ; et
- X représente :

50



50

où :


55

- a représente NH, O ou S ; et
- b et d sont identiques ou différents et représentent CH ou N

EP 0 541 120 B1

ou

5




10

où e, g et h sont identiques ou différents et représentent CH ou N ;

15

Q représente :



20

(où R³ et R⁴ sont identiques ou différents et représentent des groupes cycloalkyle en C₃₋₈ substitués ou non substitués, dans lesquels les substituants sont de 1 à 3, sont identiques ou différents, et représentent alkyle en C₁₋₆ à chaîne droite ou ramifiée, hydroxy, alcoxy en C₁₋₆ à chaîne droite ou ramifiée, halogène, nitro ou amino),

25

30




(où :

35

- Y représente une simple liaison ou alkylène en C₁₋₄ linéaire ou ramifiée ; et
- n vaut 0 ou 1),

40



45

(où :

50

- --- représente une simple ou double liaison ; et
- Y est le même que celui défini ci-dessus),

ou

55




(où Y est le même que celui défini ci-dessus) ;
ou un sel pharmacologiquement acceptable de ce dérivé.

2. Dérivé de xanthine selon la revendication 1, dans lequel :

5

- l'un parmi R¹ et R² représente alkyle en C₁₋₆ à chaîne droite ou ramifiée non substitué ; et
- l'autre représente :

10



15

3. Dérivé de xanthine selon la revendication 2, dans lequel Q représente :

20



25


4. Dérivé selon l'une quelconque des revendications 1 à 3, dans lequel ledit sel est choisi dans le groupe constitué par les sels d'addition avec les acides, les sels métalliques, les sels d'ammonium, les sels d'addition avec les amines organiques et les sels d'addition avec les acides aminés.

30

5. Composition pharmaceutique comprenant un support pharmacologiquement acceptable et, en tant qu'ingrédient actif, une quantité efficace du dérivé tel que défini par l'une quelconque des revendications 1 à 4.

6. Dérivé de xanthine de la formule (V) :

35



40

45


dans laquelle :

50

- R¹ représente alkyle en C₁₋₆ à chaîne droite ou ramifiée, substitué ou non substitué, dans lequel les substituants représentent alkyle en C₃₋₈ alicyclique, alcényle en C₂₋₄ à chaîne droite ou ramifiée, alcynyle en C₂₋₄ à chaîne droite ou ramifiée, cycloalkyle en C₃₋₈ substitué ou non substitué, phényle substitué ou non substitué, ou benzyle substitué ou non substitué, dans lequel les substituants du cycloalkyle en C₃₋₈, du phényle ou du benzyle sont de 1 à 3, sont identiques ou différents, et représentent alkyle en C₁₋₆ à chaîne droite ou ramifiée, hydroxy, alcoxy en C₁₋₆ à chaîne droite ou ramifiée, halogène, nitro ou amino ;

55

- R² représente :




EP 0 541 120 B1

où :

- m vaut 2 ou 3 ; et
- X représente :

5

10



15


où :

- a représente NH, O ou S,
- b et d sont identiques ou différents et représentent CH ou N,

ou

20

25




où e, g et h sont identiques ou différents et représentent CH ou N ;

- Q représente :

30

35



40

(où R³ et R⁴ sont identiques ou différents et représentent cycloalkyle en C₃₋₈ substitué ou non substitué, dans lequel les substituants sont de 1 à 3, sont identiques ou différents, et représentent alkyle en C₁₋₆ à chaîne droite ou ramifiée, hydroxy, alcoxy en C₁₋₆ à chaîne droite ou ramifiée, halogène, nitro ou amino),

45




50

(où :

- Y représente une simple liaison ou alkylène en C₁₋₄ à chaîne droite ou ramifiée ; et
- n vaut 0 ou 1) ;

55

5



10

(où :

- --- représente une simple ou double liaison ; et
- Y est le même que celui défini ci-dessus),

ou

15

20


(où Y est le même que celui défini ci-dessus).

25 7. Dérivé de xanthine selon la revendication 6, dans lequel :

- R^1 représente alkyle en C_{1-6} à chaîne droite ou ramifiée, non substitué ; et
- R^2 représente :

30

35



8. Dérivé de xanthine selon la revendication 7, dans lequel Q représente :

40

45



50

55